SynthesisFrontiers in oncology2026
Risk factors for infections in patients with multiple myeloma: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple myeloma (MM) is a malignant clonal disease originating from plasma cells. Patients with MM are prone to infections due to factors such as impaired immune function, bone marrow suppression, and anticancer therapy. A systematic review and meta-analysis of risk factors for infections in patients with MM provides evidence-based guidance for clinical risk assessment and intervention. Methods: Search databases such as PubMed, Web of Science, Embase, Cochrane Library, from the establishment of the database to July 20, 2025, to include observational studies evaluating risk factors for infection in patients with MM. Use the NOS tool for literature quality assessment and perform meta-analysis using Stata 15.0 to combine odds ratios (OR) and 95% confidence intervals (CI). Results: This study included 15 articles (1 case-control study and 14 cohort studies), involving 4,717 participants. The results of this meta-analysis suggest that age > 65 [OR = 1.72, 95% CI (1.18, 2.48)], male [OR = 1.70, 95% CI (1.11, 2.62)], smoking [OR = 2.97, 95% CI (1.94, 4.57)], International Staging System III [OR = 2.22, 95% CI (1.81, 2.73)], diabetes [OR = 2.67, 95% CI (1.74, 4.09)], immunomodulatory drugs [OR = 3.40, 95% CI (2.29, 5.07)], hemoglobin <10 g/dL[OR = 2.28, 95% CI (1.65, 3.16)], creatinine ≥ 2 mg/dL[OR = 2.80, 95% CI (2.07, 3.79)] was significantly associated with infection in patients with multiple myeloma. Conclusion: This systematic review and meta-analysis indicate that age >65 years, male gender, smoking, ISS stage III, diabetes, use of immunosuppressive agents, hemoglobin <10 g/dL, and creatinine ≥2 mg/dL are all significant risk factors for infection in MM patients. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251065706.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.